NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Saturday, November 21, 2009 11:34 AM

Risperdal

Type: Keyphrase

Name: Risperdal

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents

Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3cc845/cns_therapeutics) has announced the addition of the "" report to their offering.While the available CNS therapies can slow down deteriorating condition of ... [Business Wire UK - 11/19/2009]

Entities: Therapeutics, Central Nervous System, United States, market analysis

First Reported 19 hours ago - Updated 19 hours ago - 1 Documents (in Health)

How We Pay for Big Pharma's Malpractice

One reason drug companies need additional revenue is because employee whistleblowers have found the nerve to report the industry's crooked business practices—leading to multi-million dollar payouts to injured patients plus fines for legal violations. ... [Mother Jones - 19 hours ago]

Entities: Whistle-Blower, MALPRACTICE, David Franklin, Bextra

First Reported 17 hours ago - Updated 17 hours ago - 1 Documents

NHS - Click to view image in its original context

NHS

NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids

Britain's National Health Service is losing a fight against the Bonkers Institute for Nearly Genuine Research -- a web site that publicizes the underbelly of psychiatric medicine -- over brochures for children that tell them how to take antipsychotic ... [BNET - 17 hours ago]

Entities: Antipsychotic, NHS, Risperdal, Johnson & Johnson

First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Health)

Alkermes Inc

Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence

Leerink Swann upgrades Alkermes (Nasdaq: ALKS) from Market Perform to Outperform.Leerink analyst says, "Yesterday, ALKS reported positive Phase III results from its Vivitrol in opioid dependence trial. We believe this is positive for the company as it ... [Street Insider - 11/17/2009]

Entities: opioid, Alkermes Inc, Leerink Swann & Co Inc

First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents

Johnson & Johnson

Johnson & Johnson Q3 2009 Earnings Call Transcript

8:30 am ET ExecutivesLouise Mehrotra - Vice President, Investor RelationsAlex Gorsky - Worldwide Chairman of our Medical Devices & Diagnostics Group Dominic Caruso - Vice President, Finance and Chief Financial OfficerAnalystsRick Wise - Leerink SwannMatt ... [Seeking Alpha - 11/16/2009]

Entities: Johnson & Johnson, Risperdal, Medical Devices

First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents

Point Blank Advertising bags global healthcare & Rx Club award 2009

Point Blank Advertising Private Limited, a leading healthcare communication agency of India, has won three Global Healthcare Awards and one Global Trophy Award at 'Global Award 2009' function held at Bel Mondo, Sydney. Mumbai based, Point Blank Advertising ... [PharmaBiz - 11/17/2009]

Entities: Health Care, Mumbai, Risperdal, Advertising Agency

First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Internet & IT)

Johnson & Johnson Q2 2007 Earnings Call Transcript

8:30 am ET ExecutivesLouise Mehrotra - Vice President of Investor RelationsDominic Caruso - Vice President of Finance and Chief Financial OfficerAnalystsMike Weinstein – JP MorganGlenn Reicin - Morgan StanleyLarry Biegelsen - WachoviaRick Wise - Bear ... [Seeking Alpha - 11/18/2009]

Entities: United States, Johnson & Johnson, Acquisition

First Reported 11/05/2009 - Updated 11/06/2009 - 4 Documents (in Market News)

Alkermes Slips To Loss In Q2, Revises FY10 View - Update

11/5/2009 8:07 PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Thursday, Alkermes Inc. (ALKS: News ), an integrated biotechnology company, reported a second quarter loss from a profit last year. The company also revised its guidance for the ... [RTTNews.com - 11/06/2009]

Entities: Alkermes Inc, Risperdal, Del.icio.us

First Reported 10/27/2009 - Updated 10/28/2009 - 8 Documents

Antipsychotics associated with significant weight gain in children

Children and adolescents who take second-generation antipsychotic medication are significantly more likely to experience weight than those who do not, latest research suggests.US researchers studied 272 paediatric patients, aged four to 19, who were treated ... [Nursing Times - 10/28/2009]

Entities: Risperdal, Glucose, Overweight

First Reported 11/03/2009 - Updated 11/03/2009 - 3 Documents (in Health)

Johnson & Johnson to slash 7,000 - 8,000 jobs

Johnson & Johnson said on Tuesday it plans to cut 6 percent to 7 percent of its workforce in a battle to prop up profits in the face of generic competition to its prescription drugs.The company said the cuts will affect 7,000 to 8,000 jobs, and generate ... [New York Daily News - 11/03/2009]

Entities: Johnson & Johnson, William Weldon, Risperdal, Layoffs

First Reported 11/03/2009 - Updated 11/03/2009 - 2 Documents

J&J to cut 6-7 percent of workforce in restructuring

J&J said the planned restructuring will eliminate 7,000 to 8,000 jobs and generate annualized cost savings of $1.4 billion to $1.7 billion by 2011, with $800 million to $900 million expected to be achieved in 2010.'This is what we need to do to right-size ... [Exec Digital US - 11/03/2009]

Entities: Johnson & Johnson, Risperdal, William Weldon

First Reported 11/03/2009 - Updated 11/03/2009 - 2 Documents

J&J to slash workforce by at least 6%

Johnson & Johnson, the worldâs biggest health-care company, said it will cut 6% to 7% of its workforce as part of a restructuring plan.The cuts will save as much as US$1.7 billion by 2011, the New Brunswick, New Jersey-based business said on Tuesday ... [Canada.com - 11/03/2009]

Entities: Johnson & Johnson, William Weldon, Risperdal

Quotes

Leerink analyst says, "Yesterday, ALKS reported positive Phase III results from its Vivitrol in opioid dependence trial. We believe this is positive for the company as it helps reduce the dependence on Byetta LAR and Risperdal Consta for valuation. We are upgrading ALKS to Outperform on favorable risk/reward surrounding all three of its key value drivers. The opioid dependence indication may revive for Vivitrol sales; Risperdal Consta erosion will likely be minimal in the near term; and Byetta LAR is likely to obtain approval, though timing is uncertain...The main competitor to Vivitrol in opioid dependence will be Subutex/Suboxone, which are currently sold by Reckitt Benckiser (in the US and Australia) and Merck (in EU and other countries). The two drugs are on track to do about $1b in sales worldwide. Unlike Subutex/Suboxone, Vivitrol is an opioid receptor antagonist rather than a partial agonist -- which removes the worries about developing dependence to the drug. Although Suboxone lost its orphan drug marketing exclusivity earlier this quarter, we do not believe the availability of partial agonist generics will seriously curtail the potential sales of Vivitrol."

Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid De ... [Street Insider - 11/17/2009]

...of the company's pharmaceutical division earlier in the year, said:Like all of the industry we're looking at the new commercial model and asking, "How do we go to market differently? The planned job cuts at J&J, that could actually effect as many as 8,200 employees overall, may be subject to consultation procedures in certain countries where J&J has a presence."

Johnson & Johnson Cutting up to 7 Percent of Global Workforce [Digital Journal - 11/04/2009]

...4 billion and 1.7 billion a year starting in 2011, which "will provide additional resources to invest in new growth platforms." It also confirmed its earnings guidance for 2009 of $4.54 to $4...

J&J chief calls job cuts 'difficult' [TheDeal.com - 11/03/2009]

More Content

sort by: Date \| Relevance
Parent training complements medication for trea... [EurekAlert! - 12 hours ago]
NHS Loses Fight Over Publication of Antipsychot... [BNET - 17 hours ago]
How We Pay for Big Pharma's Malpractice [Mother Jones - 19 hours ago]
Atypical Antipsychotics for Treating Major Depr... [Consultant Live - 11/20/2009]
Research and Markets: Central Nervous System Th... [Business Wire - 11/19/2009]
Research and Markets: Central Nervous System Th... [Business Wire UK - 11/19/2009]
Research and Markets: Special Report - The Auti... [Forbes.com - 11/18/2009]
Research and Markets: Special Report - The Auti... [RBC Dain Rauscher - 11/18/2009]
Research and Markets: Special Report - The Auti... [Business Wire UK - 11/18/2009]
Johnson & Johnson Q2 2007 Earnings Call Tra... [Seeking Alpha - 11/18/2009]
4-Star Stocks Poised to Pop: Alkermes [Motley Fool via MSN Money - 11/17/2009]
4-Star Stocks Poised to Pop: Alkermes [Motley Fool - 11/17/2009]
U.S. FDA advisory meetings through March 25 [London South East - 11/17/2009]
Alkermes Initiates Phase 2 Clinical Study of AL... [Yahoo! Canada - 11/17/2009]
Alkermes Initiates Phase 2 Clinical Study of AL... [Business Wire - 11/17/2009]
Leerink Swann Upgrades Alkermes (ALKS) to Outpe... [Street Insider - 11/17/2009]
Point Blank Advertising bags global healthcare ... [PharmaBiz - 11/17/2009]
www.Xtremepicks.Com: Xtremepicks Alerts Novembe... [TMC Net - 11/17/2009]
xtremepicks.com: www.Xtremepicks.Com: Xtremepic... [TMC Net - 11/16/2009]
Johnson & Johnson Q3 2009 Earnings Call Tra... [Seeking Alpha - 11/16/2009]
Teva Pharmaceutical Industries Limited - Financ... [OfficialSpin - 11/14/2009]
Business news in brief [Philadelphia Inquirer - 11/14/2009]
FDA tackles online marketing [Investors Business Daily - 11/13/2009]
UK study warns against anti-psychotics for deme... [London South East - 11/12/2009]
Warning against anti-psychotics for dementia [Reuters UK - 11/12/2009]
Cramer Jeers J&J, Applauds Abbott [CNBC - 11/11/2009]
Reportlinker Adds Injectable Drug Delivery: Mar... [Earthtimes.org - 11/10/2009]
Alkermes Moves to Loss but Beats [Individual.com - 11/10/2009]
Novartis rueful after Fanapt about-face [Reuters UK - 11/09/2009]
Novartis rueful after Fanapt about-face [Reuters - 11/09/2009]

Blogs

sort by: Date \| Relevance
Dr. Peter Breggin: The Fort Hood Shooter: A Dif... [The Huffington Post Full Blog Feed - 11/08/2009] Before I begin to look at his role as a psychiatrist, I want to confirm that Major Nidal Malik Hasan was driven by religious ideology. For years he openly ...
Antipsychotic Drugs, Elderly Patients and Omnic... [WSJ.com: Health Blog - 11/04/2009] So Omnicare, a big pharmacy that specializes in providing drugs to nursing-home patients, will pay $98 million to settle allegations that the company “solicited ...
Dr. Peter Breggin: Antipsychotic Drugs, Their H... [The Huffington Post Full Blog Feed - 10/31/2009] There are many problems within our legal system that could benefit from reform. But within the area in which I have great experience as a psychiatric ...
Why Do Antipsychotic Meds Cause Weight Gain in ... [WSJ.com: Health Blog - 10/27/2009] Kids taking the latest generation of antipsychotic meds gain significant amounts of weight–as much as 19 pounds on average in just 11 weeks for kids taking Zyprexa, ...
Johnson & Johnson Solid, Yet Sales Fall [Healthcare Sector and Stocks Analysis from Seek ... - 10/13/2009] Ockham Research submits: “This is almost a microcosm of everything people are saying; cost cutting and beating on the bottom line is not going to be enough this ...

Change Password

Log in to Silobreaker

Advanced Search Options

Risperdal